Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul 7:15:137.
doi: 10.1186/s12866-015-0473-x.

Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms

Affiliations

Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms

Susana Sánchez-Gómez et al. BMC Microbiol. .

Abstract

Background: Infections by Pseudomonas aeruginosa constitute a serious health threat because this pathogen -particularly when it forms biofilms - can acquire resistance to the majority of conventional antibiotics. This study evaluated the antimicrobial activity of synthetic peptides based on LF11, an 11-mer peptide derived from human lactoferricin against P. aeruginosa planktonic and biofilm-forming cells. We included in this analysis selected N-acylated derivatives of the peptides to analyze the effect of acylation in antimicrobial activity. To assess the efficacy of compounds against planktonic bacteria, microdilution assays to determine the minimal inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and time-kill studies were conducted. The anti-biofilm activity of the agents was assessed on biofilms grown under static (on microplates) and dynamic (in a CDC-reactor) flow regimes.

Results: The antimicrobial activity of lipopeptides differed from that of non-acylated peptides in their killing mechanisms on planktonic and biofilm-forming cells. Thus, acylation enhanced the bactericidal activity of the parental peptides and resulted in lipopeptides that were uniformly bactericidal at their MIC. In contrast, acylation of the most potent anti-biofilm peptides resulted in compounds with lower anti-biofilm activity. Both peptides and lipopeptides displayed very rapid killing kinetics and all of them required less than 21 min to reduce 1,000 times the viability of planktonic cells when tested at 2 times their MBC. The peptides, LF11-215 (FWRIRIRR) and LF11-227 (FWRRFWRR), displayed the most potent anti-biofilm activity causing a 10,000 fold reduction in cell viability after 1 h of treatment at 10 times their MIC. At that concentration, these two compounds exhibited low citotoxicity on human cells. In addition to its bactericidal activity, LF11-227 removed more that 50 % of the biofilm mass in independent assays. Peptide LF11-215 and two of the shortest and least hydrophobic lipopeptides, DI-MB-LF11-322 (2,2-dimethylbutanoyl-PFWRIRIRR) and DI-MB-LF11-215, penetrated deep into the biofilm structure and homogenously killed biofilm-forming bacteria.

Conclusion: We identified peptides derived from human lactoferricin with potent antimicrobial activity against P. aeruginosa growing either in planktonic or in biofilm mode. Although further structure-activity relationship analyses are necessary to optimize the anti-biofilm activity of these compounds, the results indicate that lactoferricin derived peptides are promising anti-biofilm agents.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time-killing curves of peptides and lipopeptides at their MBC against P. aeruginosa PAO1 strain. a LF11-215 and their N-acylated derivatives; (b) LF11-322 derivatives (amino acids insertion and acyl chain addition at N-termini); (c) LF11-227 and their N-acylated derivatives
Fig. 2
Fig. 2
Effect of peptide treatment (at 10 times the planktonic MIC) on P. aeruginosa biofilms. Biofilms were grown in (a) microtiter plates (static conditions) and antibiofilm activities were determined by the MTT assay (disinfecting activity) and CV stain (removal activity); (b) CDC-reactor (turbulent conditions) and treated with 10 times the MIC of the indicated compound for 24 h at 37 °C. Live cells show green fluorescence due to GFP expression, whereas dead cells appear red because of the uptake of propidium iodide. Sodium hypochlorite at 500 μg/ml was used as an antimicrobial positive control. Scale Bars = 20 μm. LF-322 treated biofilms were not selected for fluorescence analysis since no activity against biofilm in microplates assays was found
Fig. 3
Fig. 3
Log reduction of cell viability in P. aeruginosa biofilm grown in CDC-reactor. Concentrations used were 1, 2 and 10 times the planktonic MIC and biofilms were treated during 10 and 60 min. All experiments were performed in duplicate. ANOVA-Scheffé test was used to evaluate the statistical differences between the biofilm treated with the peptides and the untreated control incubated only with diluent buffer. *: p < 0.05; **: p < 0.01; and ***: p < 0.001
Fig. 4
Fig. 4
Bactericidal effect of peptides against P. aeruginosa biofilm grown in turbulent flow conditions (CDC-reactor). Antimicrobial activity was observed with CLSM. Live cells emit green fluorescence (due to GFP) and dead cells appear red (due to PI uptake). These images show control biofilm (no peptide treatment) and treated biofilm for 1 h at 10 times the MIC of peptides. The percentage shown in each image represented the percentage of dead cells (determined by volume). Scale Bars = 20 μm

Similar articles

Cited by

References

    1. Lodise TP, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007;51:3510–5. - PMC - PubMed
    1. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010;54:3717–3722. doi: 10.1128/AAC.00207-10. - DOI - PMC - PubMed
    1. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45:999–1007. doi: 10.1128/AAC.45.4.999-1007.2001. - DOI - PMC - PubMed
    1. Davey ME, O’Toole GA. Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev. 2000;64:847–867. doi: 10.1128/MMBR.64.4.847-867.2000. - DOI - PMC - PubMed
    1. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193. doi: 10.1128/CMR.15.2.167-193.2002. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources